IRCT20220520054929N1招募中3 期
Comparison of efficacy and tolerability of pediatric primary enuresis treatment with Solifenacin and Tolterodine in children
Zahedan University of Medical Sciences0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 5 years 至 14 years（—）
- 性别
- All
入选标准
- •Children with primary enuresis referred to the clinic of Ali Bin Abi Talib Hospital in Zahedan
- •Conscious consent to study
- •Patient availability during quarterly follow-up
- •Age 5 to 14 years
排除标准
- •Structural disorders of the urinary tract
- •Neurological bladder
- •Psychiatric diseases
- •Previous allergy to drugs
- •History of taking medication (drug therapy) for enuresis
- •Urinary incontinence
研究者
相似试验
尚未招募
不适用
Comparing the 3 different instruments in cleaning the primary teethCTRI/2019/09/021033Kabita Sahoo
尚未招募
3 期
Assessment of praziquantel medication for children living in areas where schistosomiasis is common in Bahia and SergipeRBR-86kcy37Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)
已完成
不适用
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR Eye Drops vs. Xalatan® Eye Drops for the Treatment of Ocular Hypertension and Primary Open Angle GlaucomaPrimary Open Angle GlaucomaEye DiseasesGlaucomaOcular HypertensionISRCTN80385690RDR Pharma GmbH (Germany)260
进行中（未招募）
不适用
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma, with Xalatan® 0.005% Eye DropsOcular Hypertension (IOP>22 mmHg), Primary Open Angle Glaucoma (mean defect between 0 and -12 db in a visual field)MedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaEUCTR2008-002122-10-BGRDR Pharma GmbH300
进行中（未招募）
不适用
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma, with Xalatan® 0.005% Eye Drops. A multicenter, randomized, investigator-blind, clinical trial with parallel groupsOcular Hypertension (IOP>22 mmHg), Primary Open Angle Glaucoma (mean defect between 0 and -12 db in a visual field)MedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaEUCTR2008-002122-10-LVRDR Pharma GmbH260